Home/DiscGenics/Bob Wynalek

BW

Bob Wynalek

Chief Operating & Commercialization Officer, Director

Therapeutic Areas

Degenerative Disc Disease Chronic Low Back Pain Spinal Disorders

DiscGenics Pipeline

Drug	Indication	Phase
IDCT (rebonuputemcel)	Symptomatic, mild to moderate lumbar degenerative disc disease (DDD) in adults	Phase 3

Leadership Team at DiscGenics

Chief Executive Officer & Chairman of the Board

View full DiscGenics profile